500 Global and Ashdod Port Company Unveil Batch 1 of the Ashdod Accelerator by 500
13.6.2022 11:00:00 EEST | Business Wire | Press release
500 Global, a leading global venture capital firm, and Ashdod Port Company (“Ashdod Port”), the national port of Israel, unveiled today 12 startups in Batch 1 of the Ashdod Port Accelerator by 500. They hail from Israel, with one startup based in Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220612005046/en/
500 Global and Ashdod Port Company partnered in January 2022 to mentor startups and help them test and validate partnership opportunities with Ashdod Port. The Ashdod Port Accelerator by 500 program consisted of 12 weeks of masterclasses and dedicated coaching in areas such as business strategy, sales & marketing, and fundraising from 500 Global’s network of expert mentors. The program is followed by participation in an accelerated proof-of-concept for five to six months, with the potential for investment by Ashdod Port.
Program graduates in this first cohort are addressing solutions to issues in energy, logistics, seaport operations, and shipping. They will continue to work on their proof-of-concept at Ashdod Port through October, with the help of trained port personnel. On June 22, 2022, they will present their initiatives in Ashdod at the Blue Ocean for Startups event, which will also be streamed via webcast to a curated audience of industry leaders and ecosystem players.
This exclusive event features a panel of industry experts who will share insights into the role of startups in shaping innovation, as well as trends and investment opportunities in the maritime sector in Israel and around the world.
“Ashdod Port, The Port of Israel, is proud to be a leader in the innovation industry, providing beta sites for startups and supporting new technologies in the maritime sector. With a goal of being not only the biggest, but also the smartest port in Israel, Ashdod Port has set itself a goal to support innovation. We're proud of our relationship with 500 Global, and to offer one of the only accelerator programs that runs in a port. There is no doubt that the port will become a major player in the ecosystem soon. We are happy to host our Demo Day here at the port on June 22nd, and present to you how, in a short period of time, the program developed momentum and was able to promote the startups in a variety of ways–thanks to the program and the people from the port who accompany them,” said Roy Avrahami, CIO of Ashdod Port.
“Our Ashdod Port Accelerator by 500 is a truly unique initiative, thanks to our partner’s vision and belief that technology can play a central role in modernizing the maritime industry. As a result, Ashdod stands to serve as a model for other ports. Our first batch of startups has gained a solid foundation of corporate partnerships by working with Ashdod Port, and we believe they’re set up for success in Israel and beyond,” said Ee Ling Lim, Executive Director of Global Programs at 500 Global.
"The partnership between 500 Global and Ashdod Port is a groundbreaking collaboration to strengthen the port as a key player in the Israeli innovation ecosystem. The goal of the Ashdod Port Accelerator by 500 is to create a new generation of startups that are able to address the port’s pain points and also be attractive enough to be implemented in other ports around the world. In light of this unique partnership, we look forward to supporting and participating in the upcoming Demo Day that will take place on June 22, 2022,” said Tal Chen, Partner at Deloitte Israel, and Co-Leader of Deloitte Catalyst.
To attend the Blue Ocean for Startups event, please sign up here. Learn more about the event and startups presenting here.
About 500 Global
500 Global is a venture capital firm with $2.7B in assets under management that invests early in founders building fast-growing technology companies. We focus on markets where technology, innovation, and capital can unlock long-term value and drive economic growth. We work closely with key stakeholders and advise governments and corporations on how best to support entrepreneurial ecosystems so startups can thrive. 500 Global has backed over 5,000 founders representing more than 2,600 companies operating in 81 countries. Our portfolio includes 45 companies valued at over $1 billion and 130+ companies valued at over $100 million. Our 140+ plus team members are located in more than 20 countries and bring experience as entrepreneurs, investors, and operators from some of the world’s leading technology companies.
About Ashdod Port
Ashdod Port, The Port of Israel, is the leading seaport of the State of Israel with a strategically advantageous location. Experiencing growing demand, Ashdod Port has incorporated technological advancements into its operations and has inspired other ports around the world. Ashdod Port has collaborated with other institutions and ports to establish innovation embassies that promote growth within the industry. It frequently invests in new equipment and infrastructure for private and public benefit, and supports promising early stage entrepreneurs to bolster the maritime innovation ecosystem in Israel and globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220612005046/en/
Contact information
Felicia Chiriac
Redhill
felicia.chiriac@redhill.asia
+6596445927
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
